GTX Inc

GTXI NASDAQ
1.000
+0.015
+1.52%
After Hours: 1.030 +0.03 +3.00% 17:49 05/24 EDT
Open
0.9901
Prev Close
0.9850
High
1.010
Low
0.9500
Volume
78.81K
Avg Vol (3M)
741.50K
52 Week High
25.60
52 Week Low
0.7400
% Turnover
0.33%
Market Cap
24.05M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers GTX Inc GTXI stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.
MORE >

Recently

Name
Price
%Change